(1)
S. Arebee, A. CRISPR Gene-Editing Therapies for Sickle Cell Disease and Beta- Thalassemia: Clinical Outcomes, Risks and Safety Profiles. A Systematic Review. ljmas 2025, 3 (4), 102-108. https://doi.org/10.64943/ljmas.v3i4.254.